Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Hansa Biopharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 24H's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 24H underperformed the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: 24H underperformed the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Hansa Biopharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hansa Biopharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 24H (€7.41) is trading below our estimate of fair value (€40.59)
Significantly Below Fair Value: 24H is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 24H is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 24H is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 24H's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 24H is overvalued based on its PB Ratio (6.1x) compared to the DE Biotechs industry average (3.5x).
How is Hansa Biopharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 24H is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 24H is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 24H is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 24H's revenue (50.3% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 24H's revenue (50.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 24H is forecast to be unprofitable in 3 years.
How has Hansa Biopharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 24H is currently unprofitable.
Growing Profit Margin: 24H is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 24H is unprofitable, and losses have increased over the past 5 years at a rate of -39.6% per year.
Accelerating Growth: Unable to compare 24H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 24H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 24H has a negative Return on Equity (-63.97%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Hansa Biopharma's financial position?
Financial Position Analysis
Short Term Liabilities: 24H's short term assets (SEK615.7M) exceed its short term liabilities (SEK93.9M).
Long Term Liabilities: 24H's short term assets (SEK615.7M) exceed its long term liabilities (SEK7.6M).
Debt to Equity History and Analysis
Debt Level: 24H's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: 24H's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Inventory Level: 24H has a low level of unsold assets or inventory.
Debt Coverage by Assets: 24H's debt is covered by short term assets (assets are 843.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 24H has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 24H has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -41.9% each year.
What is Hansa Biopharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 24H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 24H's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 24H's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 24H's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 24H's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Søren Tulstrup (54yo)
Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Medical AB (publ) since March 20, 2018. Mr. Tulstrup served as the Chief Executive Officer of Vifor Pharma Ltd. since Augus ...
|President & CEO||1.9yrs||no data||0.025% SEK80.3k|
|CFO & Senior VP||0.8yrs||no data||no data|
|CSO & COO||0yrs||no data||no data|
|Vice President of Finance & Administration||0.8yrs||no data||0.022% SEK72.3k|
|Head of Investor Relations||0yrs||no data||no data|
|Head of Corporate Communications||0yrs||no data||no data|
|Vice President of Global Human Resources||1.1yrs||no data||0.00090% SEK2.9k|
|Senior VP & Chief Commercial Officer||0.6yrs||no data||no data|
Experienced Management: 24H's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
|Chairman of the Board||1.9yrs||kr2.56m||0.29% SEK917.8k|
|Director||0.8yrs||no data||no data|
|Chairman of European Medical Advisory Board in Transplantation||0yrs||no data||no data|
|Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation||0yrs||no data||no data|
|Member of European Medical Advisory Board in Transplantation||0yrs||no data||no data|
|Chairman of US Medical Advisory Board in Transplantation||0yrs||no data||no data|
|Member of US Medical Advisory Board in Transplantation||0yrs||no data||no data|
Experienced Board: 24H's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 24H insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Hansa Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Hansa Biopharma AB (publ)
- Ticker: 24H
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr3.408b
- Listing Market Cap: kr321.264m
- Shares outstanding: 40.03m
- Website: https://www.hansabiopharma.com
Number of Employees
- Hansa Biopharma AB (publ)
- Scheelevägen 22
- Skåne County
- 222 63
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HNSA||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Oct 2007|
|HNSB.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Oct 2007|
|0RC7||LSE (London Stock Exchange)||Yes||Class B Shares||GB||SEK||Oct 2007|
|24H||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Oct 2007|
|HNSA N||BMV (Bolsa Mexicana de Valores)||Yes||Class B Shares||MX||MXN||Oct 2007|
Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The company’s lead drug candidate is Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), a proprietary antibody-degrading enzyme for kidney transplant patients, as well as for antibody disease and guillain barre syndrome. Its preclinical stage product candidates include Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has collaborative agreement with Axis-Shield Diagnostics Limited to develop Heparin Binding Protein (HBP)-assay, a novel diagnostic method that predicts severe sepsis in patients with infectious disease symptoms. Hansa Biopharma AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 23:27|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.